Search
Back 

2017 Announcements

2017 Announcements


September 27, 2017

The IROC Roster working group is asking for your assistance in the effort to add Imaging Facilities to the IROC Roster.   The IROC Roster will include all facilities providing diagnostic imaging (DI) and/or radiation therapy (RT) services for patients on NCTN protocols.  The facilities on the IROC Roster are also known as Providers. Enrolling Sites are able to associate with one or more Provider sites using the Provider Association application on the Regulatory tab on the CTSU website.  This application is currently available; however the majority of the Providers currently on the IROC Roster are Radiation Therapy Facilities.  This new effort will add the Diagnostic Imaging Facilities providing services to protocol patients. The IROC Roster working group has developed a new survey tool to capture information about Imaging Facilities participating in NCTN trials and are asking that Site Administrators enter information about their site imaging facilities. Read More

September 12, 2017

Robert S. Mannel, MD Appointed as an NRG Oncology Group Chairman. Read more

August 28, 2017

Labor Day holiday closures for Operations, SDMCs, Biospecimen and Serum Banks, and Biologics, Inc. Read more.

July 31, 2017
NCI Registration and Credential Repository (RCR)

The RCR is available via https://ctepcore.nci.nih.gov/rcr. The link to the RCR is posted on the CTSU website:  on the CTSU home page, under CTSU Registration Procedures, click on "The CTSU Registration page."  The RCR link is at the bottom of the page under "Resources and Links to Webpages."

July 17, 2017
Update! NCI/CTEP Registration and Credential Repository (RCR)
Click here for further information.
Click here for slides from the presentation at the 2017 NRG Oncology Meeting (v. Aug 28, 2017; posted Sept 14, 2017)
CTSU April 2017 Newsletter Excerpt
RCR Profile Checklists:
Investigator (IVR)
Non-Physician Investigator (NPIVR)
Associate Plus (AP)

July 11, 2017
Ixazomib and Pevonedistat Project Team Member Application

CTEP has released a joint project team member application (PTMA) for ixazomib and pevonedistat (Millennium-Takeda).  CTEP plans to sponsor 3-5 early phase trials with ixazomib or pevonedistat alone or in combination with other treatments in various malignancies as outlined on pages 3-4 of the PMTA soliciation. The PTMA documents are on the NRG website here.

Interested applicants should notify NRG Oncology Leadership and submit PTMA to the appropriate protocol development office.

Applicants, please submit the form to the NRG protocol development office by COB Friday, July 30, 2017. NRG Oncology will submit the application to CTEP by the deadline of August 7, 2017.

July 10, 2017
Patricia A. Ganz, MD appointed new editor-in-chief of the Journal of the National Cancer Institute

The Oxford University Press announced recently that Dr. Patricia Ganz has assumed the editorial leadership role of the Journal of the National Cancer Institute.  Dr. Ganz, distinguished professor at the UCLA Fielding School of Public Health and David Geffen School of Medicine, and Director of Cancer Prevention and Control Research at the UCLA Jonsson Comprehensive Cancer Center, is a co-chair of NRG Oncology's Patient Centered Outcomes Research Committee, a member of the NRG Oncology NCORP Steering Committee and the NRG Oncology Breast Cancer Committee.  According to Dr. Ganz, "We are interested in having NCI funded clinical trial, NCORP and CPC results published in JNCI." She replaces Carmen Allegra, MD as editor-in-chief of JNCI, a move that was precipitated by Dr. Allegra's recent assignment at NCI as the head of gastrointestinal therapeutics of the Clinical Investigations Branch at the Cancer Therapy Evaluation Program. Dr. Allegra will continue as deputy editor at JNCI. Congratulations to Dr. Ganz on this well-deserved appointment! Read more

June 26, 2017
Fed Ex Alert: Hurricane Season Starts June 2017 which may cause shipment delays
The NRG Biospecimen Bank recommends all personnel responsible for shipping biospecimens to sign up for Fed Ex Service Alerts on the Fedex website by clicking here.  NRGBB Shipping Recommendations During Fed Ex Alerts: 1. Delay shipping biospecimens on dry ice shipments to the bank until the alert is lifted. 2. Priority overnight does not guarantee overnight delivery, especially during Alerts. 3. Priority overnight shipments to the NRG Banks usually route through Tennessee, even if they originate from the same state as the destination Biobank. 4. Check the tracking number for your shipments at www.Fedex.com on a daily basis to make sure the shipments arrive. Notify the bank if a shipment is going to be delayed.
Please contact the appropriate bank directly with shipping related questions:

NRGBB-Columbus:  BPCBank@nationwidechildrens.org; 866-464-2262
NRGBB-Pittsburgh: NRGbiobankPGH@NRGOncology.org; 412-697-6611
NRGBB-SF: NRGBB@ucsf.edu; 415-476-7864

Independence Day closures
Holiday closures for the 4th of July for Operations, SDMCs, Biospecimen and Serum Banks, and Biologics, Inc. Read more.

June 12, 2017

NCI/CTEP Registration and Credential Repository (RCR)
The NCI will launch the Registration and Credential Repository (RCR) on July 31, 2017. Click here for information about recommended steps to take.  Information will be presented at the NRG Oncology Meeting, Thursday, July 13, 2017. Site staff  are also strongly encouraged to read the RCR and Delegation Task Log (DTL) section (pages 4-6) of the CTSU's Newsletter (Spring 2017 Edition).  The newsletter is posted to the CTSU website under the "Broadcast/Newsletter" tab. 

June 7, 2017
Dr. Wolmark recipient of 2017 Giants of Cancer Care® award in breast cancer

Norman Wolmark, MD, has been awarded the 2017 Giants of Cancer Care® award for recognition of his contributions in breast cancer research. The recipients of the 2017 Giants of Cancer Care® awards represent twelve categories in the field of oncology and were chosen by an elite group of oncologists and hematologists from more than 300 nominations by the oncology community. This year's award ceremony was held during a reception at the Chicago History Museum on June 1. Read more.

May 22, 2017
Memorial Day closures for Operations, SDMCs, Biospecimen and Serum Banks, and Biologics, Inc. Read more

March 14, 2017
NRG Oncology NCORP PILOT Projects
NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Prevention and Control (CPC) priorities that will provide data that will directly lead to future Phase II-III  CPC concepts.  As put forward in our core grant, CPC priorities for funding are: 

  •  Cancer prevention research aimed at identifying and evaluating interventions to reduce the risk and incidence of cancer 
  •  Cancer control research aimed at reducing the incidence and co-morbidity of cancer and its treatment focused on the four symptomatic management  themes: neurotoxicity, cardiotoxicity, lymphedema, and inflammation (including cancer-related fatigue)
  •  Survivorship and palliative care interventions aimed at reducing toxicity and symptom burden, and improving quality of life (QoL)
  •  Cancer disparity research, in collaboration with our Health Disparities Research (HDR) Program, focused on efforts to increase the participation of  minorities and underserved populations in CPC studies
  •  Integral to these priorities, are the establishment of biospecimen repositories for molecular studies. 

For full details read more

NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Care Delivery Research (CCDR) priorities that will provide data that will directly lead to future CCDR concepts.  As put forward in our core grant, CCDR priorities for funding are:

  • Implementation of guideline-based care
  • Patient-reported outcomes (PROs) 
  • Decision-making tools 
  • Patient navigation 
  • Cardiotoxicity 
  • Survivorship and surveillance 
For full details read more

March 14, 2017
CB-839 PTMA
CTEP has released a project team member application (PTMA) for 
CB-839 (Calithera Biosciences, Inc.). CTEP plans to sponsor four phase 1 combination trials of CB-839 for the treatment of NSCLC, soft tissue sarcoma, or glioma. The PTMA documents are on the NRG website here.

Interested applicants should notify NRG Oncology Leadership and submit PTMA to the appropriate protocol development office.

Applicants, please submit the form to the NRG protocol development office by COB Monday, April 3, 2017. NRG Oncology will submit the application to CTEP by the deadline of April 10, 2017.



 

Copyright 2017 by NRG Oncology